Extended criteria donors in liver transplantation: adapting donor quality and recipient
- PMID: 19376402
- DOI: 10.1016/j.transproceed.2009.02.016
Extended criteria donors in liver transplantation: adapting donor quality and recipient
Abstract
Despite the progressive increase in the number of liver transplantations, the mortality on the waiting list remains between 5% and 10%, and patients have to deal with longer waiting periods. Facing this situation, transplant centers have developed alternatives to increase the number of grafts by accepting donors who were previously considered to be inadequate, because they are at higher risk of initial poor function and graft failure or may cause disease transmission. Currently, some marginal donors are being routinely used: elderly donors, steatotic grafts, non-heart-beating donors, hepatitis C virus-positive (HCV+) or hepatitis B core antibody-positive donors. These so-called marginal or extended-criteria donors were initially used in high-risk or urgent recipients; however, the number of marginal grafts has significantly increased, forcing the transplant community toward their more rationale use to maintain excellent results of liver transplantation. In this new scenario, the adequacy between donor and recipient may be paramount. Advanced donor age seems to be related to a greater graft failure rate in HCV+ recipients. Early survival seems to be significantly reduced when steatotic grafts are used in recipients with high Model for End-stage Liver Disease (MELD) scores. Moreover, a decreased survival has been observed among high-risk patients receiving organs from marginal donors. No benefit seems to exist when high-donor risk index grafts are transplanted into recipients with low MELD Scores. The recognition of various donor groups according to their quality and the need for good donor and recipient selection must lead us to define new policies for organ allocation of marginal grafts that may come into conflict with current policies of organ allocation according to the risk of death among patients awaiting a liver transplantation.
Similar articles
-
Use of severely steatotic grafts in liver transplantation: a matched case-control study.Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8. doi: 10.1097/SLA.0b013e31815c2a3f. Ann Surg. 2007. PMID: 18043095
-
Liver transplantation in the United States: a report from the UNOS Liver Transplant Registry.Clin Transpl. 1999:23-34. Clin Transpl. 1999. PMID: 11038623
-
Liver transplantation from old donors into HCV and non-HCV recipients.Transplant Proc. 2004 Apr;36(3):527-8. doi: 10.1016/j.transproceed.2004.02.023. Transplant Proc. 2004. PMID: 15110581
-
[Usage of marginal organs for liver transplantation: a way around the critical organ shortage?].Zentralbl Chir. 2009 Apr;134(2):107-12. doi: 10.1055/s-0028-1098880. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382040 Review. German.
-
Risk of extended criteria donors in hepatitis C virus-positive recipients.Liver Transpl. 2008 Oct;14 Suppl 2:S45-50. doi: 10.1002/lt.21617. Liver Transpl. 2008. PMID: 18825715 Review.
Cited by
-
Hepatocyte Transplantation in Special Populations: Clinical Use in Children.Methods Mol Biol. 2017;1506:3-16. doi: 10.1007/978-1-4939-6506-9_1. Methods Mol Biol. 2017. PMID: 27830542 Free PMC article.
-
Organ Utilization Rates from Non-Ideal Donors for Solid Organ Transplant in the United States.J Clin Med. 2024 May 31;13(11):3271. doi: 10.3390/jcm13113271. J Clin Med. 2024. PMID: 38892982 Free PMC article.
-
Retrospective Analysis of the Impact of High- and Low-Quality Donor Livers for Patients with High-Acuity Illness.Ann Transplant. 2024 Jan 9;29:e941931. doi: 10.12659/AOT.941931. Ann Transplant. 2024. PMID: 38192097 Free PMC article.
-
The impact of major extended donor criteria on graft failure and patient mortality after liver transplantation.Langenbecks Arch Surg. 2018 Sep;403(6):719-731. doi: 10.1007/s00423-018-1704-z. Epub 2018 Aug 15. Langenbecks Arch Surg. 2018. PMID: 30112639
-
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I).J Transl Med. 2011 Jul 28;9:124. doi: 10.1186/1479-5876-9-124. J Transl Med. 2011. PMID: 21798013 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical